NASDAQ:NRXS

NeurAxis (NRXS) Stock Price, News & Analysis

$3.04
-0.05 (-1.62%)
(As of 05/17/2024 ET)
Today's Range
$2.70
$3.08
50-Day Range
$2.76
$3.59
52-Week Range
$1.80
$6.93
Volume
15,349 shs
Average Volume
9,213 shs
Market Capitalization
$20.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NRXS stock logo

About NeurAxis Stock (NASDAQ:NRXS)

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

NRXS Stock Price History

NRXS Stock News Headlines

Head to Head Comparison: NeurAxis (NRXS) and Its Competitors
Head to Head Comparison: NeurAxis (NRXS) and Its Peers
Reviewing NeurAxis (NRXS) and Its Rivals
Head to Head Analysis: NeurAxis (NRXS) vs. Its Competitors
NeurAxis (NRXS) versus Its Peers Critical Review
Head-To-Head Analysis: NeurAxis (NRXS) & Its Peers
NeurAxis Announces Highmark BCBS Policy Coverage
NeurAxis, Inc. (NRXS)
NeurAxis reports Q3 results
See More Headlines
Receive NRXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/16/2024
Today
5/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:NRXS
Fax
N/A
Employees
17
Year Founded
N/A

Profitability

Net Income
$-14,630,000.00
Net Margins
-594.55%
Pretax Margin
-594.59%

Debt

Sales & Book Value

Annual Sales
$2.46 million
Book Value
($0.27) per share

Miscellaneous

Free Float
N/A
Market Cap
$20.03 million
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Brian Carrico (Age 42)
    President, CEO & Director
    Comp: $373.58k
  • Dr. Adrian Miranda (Age 54)
    Senior VP of Science & Technology and Chief Medical Officer
    Comp: $266.35k
  • Dr. Christopher Robin Brown D.D.S. (Age 70)
    Founder, Director of Innovation & Director

NRXS Stock Analysis - Frequently Asked Questions

Should I buy or sell NeurAxis stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeurAxis in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NRXS shares.
View NRXS analyst ratings
or view top-rated stocks.

How have NRXS shares performed in 2024?

NeurAxis' stock was trading at $2.67 at the beginning of the year. Since then, NRXS shares have increased by 13.9% and is now trading at $3.04.
View the best growth stocks for 2024 here
.

How were NeurAxis' earnings last quarter?

NeurAxis, Inc. (NASDAQ:NRXS) released its quarterly earnings results on Tuesday, April, 16th. The company reported $0.29 EPS for the quarter. The firm earned $0.53 million during the quarter.

When did NeurAxis IPO?

NeurAxis (NRXS) raised $7 million in an initial public offering (IPO) on Wednesday, August 9th 2023. The company issued 1,098,667 shares at a price of $6.00 per share.

How do I buy shares of NeurAxis?

Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRXS) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners